54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 5-9 September 2014, Washington, DC
Although this large North American conference always includes a separate section in the programme on HIV, this is a conference that we are rarely able to attend.
A summary of highlights from ICAAC 2014 is included in this issue thanks to coverage on natap.org of about 60 studies. This includes hyperlinks to both longer articles and slides from oral presentations that are not otherwise available on the conference website.
The final programme is available in PDF format from the ICAAC website.
Abstracts are available using the search facility in the online programme planner, but links to individual abstracts involve long URLs that for some previous conferences are not maintained permanently.
Reports in this issue are:
- Antiretroviral studies at ICAAC 2014: darunavir-based FDC with TAF, cobicistat, doravirine, Stribild and gel formulation PrEP
- Switch from efavirenz to rilpivirine quells CNS toxicity, improves sleep
- HIV persists in lung macrophages of people on suppressive ART
- Only 10% of veterans with HCV or HCV/HIV in the US treated for HCV